Ftse Mib
34.339,32
0,55%
DAX
18.686,60
1,07%
S&P 500
5.214,08
0,51%
NASDAQ
16.346,26
0,27%
Bitcoin
62.916,49
-0,21%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Recursion Pharmaceuticals Inc (RXRX) Recursion Pharmaceuticals Inc (RXRX) Notizie

RXRX

Recursion Pharmaceuticals (RXRX)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:RXRX
DataOraFonteTitoloSimboloCompagnia
09/05/202422:11Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:RXRXRecursion Pharmaceuticals Inc
09/05/202422:01GlobeNewswire Inc.Recursion Provides Business Updates and Reports First Quarter 2024 Financial ResultsNASDAQ:RXRXRecursion Pharmaceuticals Inc
02/05/202414:00GlobeNewswire Inc.Recursion to Report First Quarter 2024 Business Updates and Financial Results on May 9NASDAQ:RXRXRecursion Pharmaceuticals Inc
01/05/202414:01GlobeNewswire Inc.Recursion to Participate in Upcoming Investor ConferencesNASDAQ:RXRXRecursion Pharmaceuticals Inc
30/04/202414:00GlobeNewswire Inc.Altitude Lab Secures Small Business Administration Growth Fund Accelerator Grant to Launch Horizon, a Commercialization Partnering ProgramNASDAQ:RXRXRecursion Pharmaceuticals Inc
16/04/202414:00GlobeNewswire Inc.Recursion Appoints Najat Khan, PhD, as Chief R&D Officer and Chief Commercial OfficerNASDAQ:RXRXRecursion Pharmaceuticals Inc
02/04/202414:00GlobeNewswire Inc.Recursion to Participate in Upcoming Investor ConferenceNASDAQ:RXRXRecursion Pharmaceuticals Inc
26/03/202413:00GlobeNewswire Inc.Recursion Publishes Annual Environmental, Social and Governance ReportNASDAQ:RXRXRecursion Pharmaceuticals Inc
11/03/202409:00GlobeNewswire Inc.Recursion Announces Plans to Open New Office in LondonNASDAQ:RXRXRecursion Pharmaceuticals Inc
09/03/202401:08Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RXRXRecursion Pharmaceuticals Inc
06/03/202423:39Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:RXRXRecursion Pharmaceuticals Inc
01/03/202420:58GlobeNewswire Inc.Recursion Hosts Second Annual Rare Disease Day Events for Utah’s Rare Disease CommunityNASDAQ:RXRXRecursion Pharmaceuticals Inc
29/02/202414:25Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:RXRXRecursion Pharmaceuticals Inc
27/02/202422:05GlobeNewswire Inc.Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2023 Financial ResultsNASDAQ:RXRXRecursion Pharmaceuticals Inc
20/02/202413:59GlobeNewswire Inc.Recursion to Host Public L(earnings) Call on February 27NASDAQ:RXRXRecursion Pharmaceuticals Inc
12/02/202418:21Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:RXRXRecursion Pharmaceuticals Inc
07/02/202422:56Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RXRXRecursion Pharmaceuticals Inc
29/01/202422:00Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:RXRXRecursion Pharmaceuticals Inc
24/01/202415:00GlobeNewswire Inc.Altitude Lab Startups Raise Over $120M in CapitalNASDAQ:RXRXRecursion Pharmaceuticals Inc
08/01/202416:59GlobeNewswire Inc.Recursion Unveils LOWE Drug Discovery Software at the J.P. Morgan Healthcare ConferenceNASDAQ:RXRXRecursion Pharmaceuticals Inc
04/01/202413:59GlobeNewswire Inc.Recursion Adds New Chemical Entity Targeting Fibrotic Diseases to Late Discovery PipelineNASDAQ:RXRXRecursion Pharmaceuticals Inc
20/12/202313:59GlobeNewswire Inc.Recursion and Enamine to Generate and Design Enriched Compound Libraries for Global Drug Discovery IndustryNASDAQ:RXRXRecursion Pharmaceuticals Inc
15/12/202314:38Edgar (US Regulatory)Form 424B7 - Prospectus [Rule 424(b)(7)]NASDAQ:RXRXRecursion Pharmaceuticals Inc
09/11/202315:41GlobeNewswire Inc.Bayer and Recursion Focus Research Collaboration on OncologyNASDAQ:RXRXRecursion Pharmaceuticals Inc
09/11/202314:01GlobeNewswire Inc.Recursion Announces Data Collaboration Deal with Tempus, Top 50 Supercomputer Ambition Powered by NVIDIA, and Updated Focus of Collaboration with Bayer to Precision OncologyNASDAQ:RXRXRecursion Pharmaceuticals Inc
09/11/202313:58GlobeNewswire Inc.Recursion Provides Business Updates and Reports Third Quarter 2023 Financial ResultsNASDAQ:RXRXRecursion Pharmaceuticals Inc
05/09/202313:59GlobeNewswire Inc.Recursion Announces Completion of Phase 1 Study for REC-3964 for Clostridioides Difficile InfectionNASDAQ:RXRXRecursion Pharmaceuticals Inc
11/08/202322:12Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:RXRXRecursion Pharmaceuticals Inc
08/08/202314:13Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:RXRXRecursion Pharmaceuticals Inc
08/08/202314:00GlobeNewswire Inc.Recursion Bridges the Protein and Chemical Space with Massive Protein-Ligand Interaction Predictions Spanning 36 Billion CompoundsNASDAQ:RXRXRecursion Pharmaceuticals Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:RXRX

La tua Cronologia

BIT
BPE
Bper Banca
BIT
UCG
Unicredit
BIT
ISP
Intesa Sanpaolo
BIT
STLAM
Stellantis NV
BIT
ENEL
Enel
BIT
NEXI
Nexi S.p.A
BIT
BAMI
Banco BPM
BIT
BMPS
Banca Monte Dei Paschi D...
BIT
PRY
Prysmian
BIT
ENI
Eni
BIT
RACE
Ferrari NV
BIT
LDO
Leonardo
BIT
STMMI
ST Microelectronics
BIT
FBK
Finecobank
BIT
TIT
Telecom Italia
BIT
SRG
Snam
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network